Evidence map›Paper›PMID 40883029›Full record

ArticleCancer genomics & proteomics

Pioglitazone Suppresses Urothelial Tumorigenesis

Nguyen Thu Quynh, Yujiro Nagata, Takuo Matsukawa, Eiji Kashiwagi, Naohiro Fujimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nguyen Thu Quynh *Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yujiro Nagata *Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; yujiro-nagata@med.uoeh-u.ac.jp.
Takuo MatsukawaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Eiji KashiwagiDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Naohiro FujimotoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPioglitazone (PIO), a peroxisome proliferator-activated receptor gamma agonist, is typically used to treat type 2 diabetes mellitus. In addition to its metabolic effects, PIO exhibits various biological activities, including potential anticancer effects. However, its efficacy and mechanistic relevance in the development and progression of cancer, including urothelial carcinoma, remain unclear. Herein, we investigated the functional impact of PIO on urothelial tumorigenesis. MATERIALS AND

methodsAn

resultsPIO significantly inhibited the neoplastic/malignant transformation of SV-HUC-1 cells. Moreover, PIO treatment up-regulated tumor suppressors, including p53 and phosphatase and tensin homolog (PTEN), as well as the epithelial marker E-cadherin, while down-regulating the mesenchymal marker N-cadherin and the oncogenic factor nuclear factor kappa B (NF-κB), as confirmed by protein and mRNA expression analyses.

conclusionPIO has a chemopreventive effect on urothelial tumorigenesis, supporting its potential use as a preferred anti-diabetic agent for patients with a risk or history of urothelial carcinoma.

Indexed as

CarcinogenesisCell Transformation, NeoplasticPioglitazoneUrinary Bladder NeoplasmsUrotheliumCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansPioglitazonebladder cancerneoplastic transformationperoxisome proliferator-activated receptor gammaPioglitazoneurothelial carcinoma

Identifiers

PMID40883029
PMCPMC12402716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.